Authors :
Ismael Coulibaly; Meryem Zaouit; Hanane Rida; Chékrine Tarik; Mouna Bourhafour; Zineb Bouchbika; Nadia Benchakroun; Hassan Jouhadi; Nezha Tawfiq; Souha Sahraou; Abou Dao
Volume/Issue :
Volume 8 - 2023, Issue 4 - April
Google Scholar :
https://bit.ly/3TmGbDi
Scribd :
https://bit.ly/3phTVEk
DOI :
https://doi.org/10.5281/zenodo.8099648
Abstract :
Oligometastatic disease is an intermediate stage
between locally advanced disease and multi-metastatic
disease. We report the experience of the Mohamed VI
Center for the Treatment of Cancers in the management
of oligometastatic prostate cancers in a retrospective
series from 2016 to 2019.
Method
We collected cases of de novo metastatic prostate
adenocarcinoma judged to be oligometastatic and having
benefited from radiotherapy on the prostate. The
primary endpoints were: progression-free survival and
overall survival at 2 and 3 years. The proportions were
compared by the CHI 2 test with a significance level of
0.05. The Kaplan Meier model was used to compare
survivals.
Result
We had recruited 37 patients with a median age of
70 years. The initial PSA was between 11 ng/ml and 1635
ng/ml with an average of 160 ng/ml. The Gleason score
was between 8 and 10 in 46 % of patients. A secondary
bone location was present in 100% of cases and no
patient had a visceral metastasis. The vertebral seat was
the most common secondary bone site (55%). The
maximum number of metastatic sites was 3. The median
follow-up is 38 months. Overall survival at 24 months
and 36 months, respectively, was 92% and 86%. The 2-
year and 3-year progression-free survival was 84% and
79%, respectively. There was no statistically significant
difference in either overall survival or progression-free
survival between patients who received radiation to the
prostate alone and those who received radiation to the
prostate plus the pelvis (p = 0.86). No significant
difference was observed in terms of survival between the
patients who received in addition to local radiotherapy
and primary palliative chemotherapy and those who
received only local radiotherapy. The low statistical
power of our sample did not allow us to obtain a
significant difference between patients irradiated in
hypofractionated and those irradiated in conventional
fractionation.
Conclusion
The limit of our study lies in the small size of our
sample but also in its retrospective nature. Prostate
radiation therapy remains a treatment option for de
novo oligometastatic prostate cancer.
Keywords :
Prostate, Adenocarcinoma, Metastasis, Radiotherapy, Morocco
Oligometastatic disease is an intermediate stage
between locally advanced disease and multi-metastatic
disease. We report the experience of the Mohamed VI
Center for the Treatment of Cancers in the management
of oligometastatic prostate cancers in a retrospective
series from 2016 to 2019.
Method
We collected cases of de novo metastatic prostate
adenocarcinoma judged to be oligometastatic and having
benefited from radiotherapy on the prostate. The
primary endpoints were: progression-free survival and
overall survival at 2 and 3 years. The proportions were
compared by the CHI 2 test with a significance level of
0.05. The Kaplan Meier model was used to compare
survivals.
Result
We had recruited 37 patients with a median age of
70 years. The initial PSA was between 11 ng/ml and 1635
ng/ml with an average of 160 ng/ml. The Gleason score
was between 8 and 10 in 46 % of patients. A secondary
bone location was present in 100% of cases and no
patient had a visceral metastasis. The vertebral seat was
the most common secondary bone site (55%). The
maximum number of metastatic sites was 3. The median
follow-up is 38 months. Overall survival at 24 months
and 36 months, respectively, was 92% and 86%. The 2-
year and 3-year progression-free survival was 84% and
79%, respectively. There was no statistically significant
difference in either overall survival or progression-free
survival between patients who received radiation to the
prostate alone and those who received radiation to the
prostate plus the pelvis (p = 0.86). No significant
difference was observed in terms of survival between the
patients who received in addition to local radiotherapy
and primary palliative chemotherapy and those who
received only local radiotherapy. The low statistical
power of our sample did not allow us to obtain a
significant difference between patients irradiated in
hypofractionated and those irradiated in conventional
fractionation.
Conclusion
The limit of our study lies in the small size of our
sample but also in its retrospective nature. Prostate
radiation therapy remains a treatment option for de
novo oligometastatic prostate cancer.
Keywords :
Prostate, Adenocarcinoma, Metastasis, Radiotherapy, Morocco
